Text Size

A Study to Evaluate the Dosing of AMG 827 for Subjects With Inadequately Controlled Asthma

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by:
Amgen
ClinicalTrials.gov Identifier:
NCT01199289
First received: August 5, 2010
Last updated: September 22, 2011
Last verified: September 2011
History of Changes
  Purpose

The purpose of this study is to determine if AMG 827 is effective compared to placebo as measured by change in Asthma Control Questionnaire (ACQ) composite scores.


Condition Intervention Phase
Asthma
 Drug: AMG 827
Drug: Placebo
 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Determine the Safety and Efficacy of AMG 827 in Subjects With Inadequately Controlled Asthma

Resource links provided by NLM:

MedlinePlus related topics: Asthma
U.S. FDA Resources

Further study details as provided by Amgen:

Primary Outcome Measures:
  • The primary objective is to determine if AMG 827 is effective compared to placebo as mesasured by change in Asthma Control Questionnaire (ACQ) composite scores from baseline to week 12. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Evaluate the efficacy of AMG 827 as measured by Pre- and post-bronchodilator FEV1 (forced expiratory volume in 1 second) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Evaluate the efficacy of AMG 827 as measured by am and pm Peak expiratory flow rate (PEFR) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Evaluate the efficacy of AMG 827 as measured by use of rescue Short Acting β-Agonist (SABA) use [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Evaluate the efficacy of AMG 827 as measured by daily asthma symptoms (aggregate/night and individual) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Evaluate the efficacy of AMG 827 as measured by Asthma Quality of Life Questionnaire (AQLQ) score [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Enrollment: 315
Study Start Date: October 2010
Estimated Study Completion Date: July 2012
Estimated Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AMG 827 280 mg
280 mg AMG 827
 Drug: AMG 827
280 mg AMG 827 SC
Placebo Comparator: Placebo
Placebo
 Drug: Placebo
Placebo SC
Experimental: AMG 827 140 mg
140 mg AMG 827
 Drug: AMG 827
140 mg AMG 827 SC
Experimental: AMG 827 210 mg
210 mg AMG 827
 Drug: AMG 827
210 mg AMG 827 SC

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men or women 18 to 65 years of age
  • Percent of predicted FEV1 ≥ 50% and ≤ 80%
  • At least 12% reversibility over pre-bronchodilator FEV1
  • Inhaled corticosteroid (ICS) ≥ 200 and ≤ 1000 µg/day fluticasone or equivalent.
  • Ongoing asthma symptoms with ACQ composite score ≥ 1.5 points

Exclusion Criteria:

  • Respiratory infection within 4 weeks of screening visit or 1 week of baseline visit
  • History of chronic obstructive pulmonary disease or other chronic pulmonary condition other than asthma
  • Any uncontrolled or clinically significant systemic disease (eg, uncontrolled diabetes, liver disease)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01199289

  Show 49 Study Locations
Sponsors and Collaborators
Amgen
Investigators
Study Director: MD Amgen
  More Information

Additional Information:
AmgenTrials clinical trials website  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Global Development Leader, Amgen Inc.
ClinicalTrials.gov Identifier: NCT01199289     History of Changes
Other Study ID Numbers: 20090203
Study First Received: August 5, 2010
Last Updated: September 22, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by Amgen:
Amgen
chronic inflammatory disease
wheezing

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
 Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases

ClinicalTrials.gov processed this record on May 22, 2013